Mechanisms of anabolic therapies for osteoporosis

被引：492

作者：

Canalis, Ernesto

Giustina, Andrea

Bilezikian, John P.

机构：

[1] St Francis Hosp & Med Ctr, Dept Res, Hartford, CT 06105 USA

[2] Univ Connecticut, Sch Med, Farmington, CT USA

[3] Univ Brescia, Dept Internal Med, Brescia, Italy

[4] Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2007年 / 357卷 / 09期

关键词：

D O I：

10.1056/NEJMra067395

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Antiresorptive agents help to restore skeletal balance by reducing bone turnover, primarily at the tissue level. Another therapeutic approach is to enhance bone formation with the use of anabolic agents, which differ fundamentally from antiresorptive drugs in their primary mechanism of action. This article reviews the mechanisms of polypeptide anabolic agents and strontium as potential therapeutic options for osteoporosis. Copyright © 2007 Massachusetts Medical Society.

引用

收藏

页码：905 / 916

页数：12

相关论文

共 80 条

[1] Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST) [J].

Balemans, W ;

Ebeling, M ;

Patel, N ;

Van Hul, E ;

Olson, P ;

Dioszegi, M ;

Lacza, C ;

Wuyts, W ;

Van den Ende, J ;

Willems, P ;

Paes-Alves, AF ;

Hill, S ;

Bueno, M ;

Ramos, FJ ;

Tacconi, P ;

Dikkers, FG ;

Stratakis, C ;

Lindpaintner, K ;

Vickery, B ;

Foernzler, D ;

Van Hul, W .

HUMAN MOLECULAR GENETICS, 2001, 10 (05) :537-543

[2] Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: A novel mechanism for hormonal control of osteoblastogenesis [J].

Bellido, T ;

Ali, AA ;

Gubrij, I ;

Plotkin, LI ;

Fu, Q ;

O'Brien, CA ;

Manolagas, SC ;

Jilka, RL .

ENDOCRINOLOGY, 2005, 146 (11) :4577-4583

[3] Regulation of osteoblastogenesis and bone mass by Wnt10b [J].

Bennett, CN ;

Longo, KA ;

Wright, WS ;

Suva, LJ ;

Lane, TF ;

Hankenson, KD ;

MacDougald, OA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (09) :3324-3329

[4] The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis [J].

Black, DM ;

Greenspan, SL ;

Ensrud, KE ;

Palermo, L ;

McGowan, JA ;

Lang, TF ;

Garnero, P ;

Bouxsein, ML ;

Bilezikian, JP ;

Rosen, CJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (13) :1207-1215

[5] One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis [J].

Black, DM ;

Bilezikian, JP ;

Ensrud, KE ;

Greenspan, SL ;

Palermo, L ;

Hue, T ;

Lang, TF ;

McGowan, JA ;

Rosen, CJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (06) :555-565

[6] High bone density due to a mutation in LDL-receptor-related protein 5 [J].

Boyden, LM ;

Mao, JH ;

Belsky, J ;

Mitzner, L ;

Farhi, A ;

Mitnick, MA ;

Wu, DQ ;

Insogna, K ;

Lifton, RP .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (20) :1513-1521

[7] Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein [J].

Brunkow, ME ;

Gardner, JC ;

Van Ness, J ;

Paeper, BW ;

Kovacevich, BR ;

Proll, S ;

Skonier, JE ;

Zhao, L ;

Sabo, PJ ;

Fu, YH ;

Alisch, RS ;

Gillett, L ;

Colbert, T ;

Tacconi, P ;

Galas, D ;

Hamersma, H ;

Beighton, P ;

Mulligan, JT .

AMERICAN JOURNAL OF HUMAN GENETICS, 2001, 68 (03) :577-589

[8] The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro [J].

Canalis, E ;

Hott, M ;

Deloffre, P ;

Tsouderos, Y ;

Marie, PJ .

BONE, 1996, 18 (06) :517-523

[9] Bone morphogenetic proteins, their antagonists, and the skeleton [J].

Canalis, E ;

Economides, AN ;

Gazzerro, E .

ENDOCRINE REVIEWS, 2003, 24 (02) :218-235

[10] The fate of circulating osteoblasts [J].

Canalis, E .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (19) :2014-2016

← 1 2 3 4 5 6 7 8 →